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1. Introduction
The aortic valve separates the left ventricular outflow tract from the aorta. It is a tricuspid valve
consisting of three semilunar cusps and the aortic valve annulus. The aortic valve annulus is
a collagenous structure lying at the level of the junction of the aortic valve and the ventricular
septum, which is the nadir of the aortic valve complex. This area is also referred to as the aortic
ring and serves to provide structural support to the aortic valve complex. The annulus is
shaped like a crown and extends to the level of the aortic sinuses. It attaches to the aortic media
distally and the membranous and muscular ventricular septum proximally and anteriorly.
There are 3 aortic valve cusps, each half-moon shaped or semilunar in appearance. A small
dilatation of the proximal aorta is associated with each cusp; collectively, these are referred to
as the sinuses of Valsalva or aortic sinuses, named after the Italian anatomist Antonio Valsalva.
Their association with the respective coronary ostia identifies them: left, right, and posterior
(or noncoronary).[1]
Aortic stenosis (AS) is one of the most common diseases of the aortic valve. The most common
causes of AS are degenerative calcification, bicuspid aortic valve and rheumatic etiology. Age
– related degenerative calcific AS is currently the most common cause of AS in adults and most
frequent reason for aortic valve replacement (AVR).[2] That atherosclerosis is a cause of AS is
derived primarily from five pieces of evidence: 1) that patients with familial homozygous
hyperlipidemia usually develop calcific deposits on the aortic aspects of their aortic valve cusps
at a very young age, usually by the teenage years (These individuals have serum total
cholesterol levels >800 mg/dl from the time of birth.); 2) that progression of AS can be slowed
by lowering total and low-density lipoprotein cholesterol levels by statins; 3) that patients >65
years of age with AS involving a three-cuspid aortic valve (unassociated with mitral valve
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disease) usually have extensive atherosclerosis involving the major epicardial coronary
arteries and usually other systemic arterial systems; 4) that serum total cholesterol levels and
concomitant coronary bypass grafting tend to be higher in patients with AS involving three-
cuspid aortic valves than in patients of similar age and sex without AS or with congenitally
bicuspid aortic valves; and 5) that histologic study of three-cuspid stenotic aortic valve
demonstrates features similar to those in atherosclerotic plaques.[2] Rare causes of aortic
stenosis include obstructive, infective endocarditis, Paget’s disease, renal failure, drug
induced, familial hypercholesterolemia, systemic lupus erythematosus, irradiation, and
ochronosis.[3] As the valves stenosis, valvular abnormality produces turbulent flow, which
traumatizes the leaflets and eventually leads to progressive cell proliferation, extracellular
matrix production, and calcification of the valve. It is degenerative process that leads to
proliferative and inflammatory changes that leading to calcification of the aortic valve.
Progressive calcification leads to immobilization of the cusps.[3]
Figure 1. Normal aortic valve and stenotic aortic valve
The pathophysiology of valvular aortic stenosis is one of progressive obstruction and the
resultant compensatory changes. With increasing left ventricular outflow tract obstruction,
there is pressure hypertrophy of the left ventricle. Left ventricular cavity size and systolic
function is initially maintained, as the increase in left ventricular wall thickness acts as a
compensatory mechanism to normalize wall stress. The development of pressure hypertrophy
is initially a beneficial adaptation. However, this hypertrophy may result in reduced coronary
flow reserve and oxygen supply–demand mismatch. These hypertrophied hearts are also more
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sensitive to diffuse subendocardial ischemic injury, which may result in both systolic and
diastolic dysfunction. As the obstruction progresses to a critical level, the high afterload
“overwhelms” the left ventricle and systolic function begins to decrease. With continued
severe afterload excess, myocyte degeneration and fibrosis occurs and produces irreversible
left ventricular systolic dysfunction. In these patients, both the high afterload and the intrinsic
myocardial disease significantly increase wall stress and a vicious cycle of deterioration in
ventricular function ensues.[3]
The evaluation of aortic stenosis is based upon the history, the physical examination, and a
comprehensive echocardiography. For most patients, two-dimensional echocardiography
readily identifies the calcified stenotic aortic valve, and Doppler echocardiography reliably
estimates the severity of aortic stenosis in the majority of patients. Many patients with aortic
stenosis will remain asymptomatic for decades. The diagnosis of aortic stenosis is usually made
in the asymptomatic patient on the basis of a systolic murmur on auscultation and confirmed
by echocardiography. Symptoms, when they occur, usually consist of one or more of the classic
triad of exertional dyspnea, angina, and syncope. Following symptom onset, there is a high
mortality rate with an average survival of 2–3 years. The development of symptoms therefore
is a critical point in the natural history of patients with aortic stenosis. Sudden death rarely is
the initial manifestation of severe aortic stenosis, occurring at a rate of less than 1% per year
in asymptomatic patients.[3] Two-dimensional and Doppler echocardiography is the imaging
modality of choice for the diagnosis and quantification of aortic stenosis. Short-axis images
from two-dimensional echocardiography demonstrate the number of aortic cusps and the
degree of cusp fusion or restricted cusp opening in valvular aortic stenosis. Two dimensional
echocardiography is also useful for determining the status of the left ventricle and the degree
of hypertrophy. Left atrial enlargement indicates concomitant diastolic dysfunction. The
normal area of the adult aortic valve is 3.0 to 4.0 cm2. Reduction of the normal area usually
does not produce symptoms until the valve reaches one-fourth of its normal dimension.[4] The
graduation of AS is given in Table 1.
Severity Aortic jet velocity
(m per second)
Mean gradient
(mm Hg)
Aortic valve area
(cm2)
Normal < 2.5 - 3 to 4
Mild 2.5 to 2.9 < 25 1.5 to 2
Moderate 3 to 4 25 to 40 1 to 1.5
Severe > 4 > 40 < 1
Table 1. Classifications of Aortic Stenosis Severity4
There is no effective medical therapy for AS. AVR is the only effective treatment for severe
aortic stenosis in adults. Following AVR for AS, one can expect resolution of symptoms, left
ventricular hypertrophy (LVH) regression, and improved left ventricular (LV) systolic
function secondary to reduced afterload. Importantly, postoperative survival is similar to age-
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matched controls after AVR for AS when performed prior to the development of LV dysfunc‐
tion or congestive heart failure (CHF). Similarly, incomplete regression of LVH after AVR has
been associated with adverse outcomes such as reduced long-term survival. Contrary to the
immediate improvement in systolic performance, diastolic dysfunction may persist for several
more years after AVR. In fact, Gjertsson et al. recently evaluated diastolic dysfunction in AS
and found that the proportion of patients with moderate-to-severe diastolic dysfunction
actually increased with time after AVR despite normalization of LV mass and appropriate
adjustments for senile diastolic dysfunction. Finally, AVR is associated with improved quality
of life scores, particularly among the elderly, and has been found to be similar to age-matched
individuals without heart disease. [3,5,6]
The American College of Cardiology (ACC) and the American Heart Association (ACH) have
jointly developed guidelines in which they published indications for AVR:
a. Definite indications:
• Patients who have severe AS and presented with one or more of its classical symptoms
(angina, syncope, heart failure, etc.)
• Patients who have severe AS and required coronary artery bypass surgery, surgery on
the aorta or other heart valves
• Patients who have severe AS and left ventricle systolic dysfunction (ejection fraction
less than 50 %)
b. Possible indications:
• Patients who have moderate AS and required coronary artery bypass surgery, surgery
on the aorta or other heart valves
• Asymptomatic patients with severe AS with abnormal exercise test, or an increase in
transaortic gradient during exercise, or left ventricle systolic dysfunction (ejection
fraction less than 50 %), or left ventricular dilatation, or significantly elevated left
ventricular diastolic pressure. [7]
The European Society of Cardiology (ESC) has also developed guidelines in which they
published indications for AVR (Table 2).[8] They strongly recommended early AVR in all
symptomatic patients with severe AS.
Management of asymptomatic patients requires careful weighing of benefits against risks.
Early elective surgery at these patients can only be recommended in selected patients, at low
operative risk. This could be the case in:
• The rare asymptomatic patients with depressed LV function not due to another cause
• Those with echocardiographic predictors of poor outcome suggested by the combination of
a markedly calcified valve with a rapid increase in peak aortic velocity of ≥ 0.3 m/s per year
• If the exercise test is abnormal, particularly if it shows symptom development, which is a
strong indication for surgery in physically active patients.
Calcific Aortic Valve Disease364
• However, on the other hand, breathlessness on exercise may be difficult to interpret in
patients with only low physical activity, particularly the elderly, making decisionmaking
more difficult. There is no strict age limit for performance of exercise testing and it is
reasonable to propose it in patients > 70 years old who are still highly active.[8]
Patients with severe AS and any symptoms IB
Patients with severe AS undergoing coronary artery bypass surgery, surgery of the ascending aorta, or
on another valve
IC
Asymptomatic patients with severe AS and systolic LV dysfunction (LVEF < 50%) unless due to other
cause
IC
Asymptomatic patients with severe AS and abnormal exercise test showing symptoms on exercise IC
Asymptomatic patients with severe AS and abnormal exercise test showing fall in blood pressure
below baseline
IIaC
Patients with moderate AS undergoing coronary artery bypass surgery, surgery of the ascending aorta
or another valve
IIaC
Asymptomatic patients with severe AS and moderate-to-severe valve calcification, and a rate of peak
velocity progression ≥ 0.3 m/s per year
IIaC
AS with low gradient (< 40 mmHg) and LV dysfunction with contractile reserve IIaC
Asymptomatic patients with severe AS and abnormal exercise test showing complex ventricular
arrhythmias
IIbC
Asymptomatic patients with severe AS and excessive LV hypertrophy (≥ 15 mm) unless this is due to
hypertension
IIbC
AS with low gradient (< 40 mmHg) and LV dysfunction without contractile reserve IIbC
Table 2. Indications for AVR in AS
In last 50 years, the varieties of prostheses that have become available for use are numer‐
ous.  An  ideal  aortic  prosthesis  would  be  simple  to  implant,  widely  available,  possess
long-term durability, would have no intrinsic thrombogenicity, would not have a predilec‐
tion foe endocarditis and would have no residual transvalvular pressure gradient. Such a
valve  does  not  currently  exist.  Currently  available  options  include  mechanical  valves,
stented biological valves, stentless biological valves, allograft valves and pulmonary auto‐
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graft valves. Commonly in us are mechanical and biological prostheses.[9] When selecting
between mechanical and biologic heart valves, the surgeon and patient must balance the
risks and benefits of each choice.
2. Mechanical prostheses
Charles Hufnagel in 1952. Used aortic valve ball and cage prosthesis heterotopically in the
descending aorta to treat aortic insufficiency. The first aortic valve replacement with an intra
cardiac mechanical prosthesis, which led to long terms survivors, was performed in 1960.
Mechanical valves are classified according to their structure as caged-ball, single-tilting-disk
or bileaflet-tilting-disk valves. The Starr-Edwards caged-ball valve has been available since
the 1960’s and comprises a silastic ball, which rests on the sewing ring when closed and moves
forward into the cage when the valve opens. The single-disk valves, for example, the Bjork-
Shiley prosthesis and the Medtronic-Hall prosthesis, contain a disk that tilts between two struts
of the orifice housing. The most popular of the mechanical valves at present are the bileaflet
valves, of which the St. Jude Medical valve and the Carbomedics valve are widely implanted.
Both these devices are implanted within the aortic annulus. The two semi-circular leaflets of
the bileaflet valve are connected to the housing by a butterfly hinge mechanism and swing
apart during opening of the valve creating three outflow tracts, one central and two peripheral
respectively. In contrast to the configuration of the latter, the Carbomedics Top Hat (Sulzer
Carbomedics, Austin, TX) bileaflet aortic valve that was introduced in 1993 has a unique supra-
annular design with all its components incorporated within the aortic sinuses.[10,11]
Mechanical valves are made from carbon, Teflon, Dacron, titanium and polyester and are
very durable. The current designs for the aortic and mitral positions include ball-and-cage
valves, single tilting disc prostheses, and bileaflet prostheses.  Bileaflet mechanical valves
are the standard in current practice, with the St. Jude Medical (St. Jude Medical, Inc., St.
Paul, MN) prosthesis the modern prototype, having been first implanted in 1977. Most of
these  valves  are  constructed  using  carbon  strengthened  with  silicon  carbide  additives.
Other examples of bileaflet mechanical valves include those manufactured by CarboMed‐
ics  (Austin,  TX);  Advancing  the  Standard  Medical  (ATS,  Minneapolis,  MN);  Medtronic,
Inc. (Minneapolis, MN); and Medical Carbon Research Institute, LLC (MCRI, Austin, TX).
[10,11,12] The On-XR mechanical valve (MCRI) was introduced in Europe in 1996 and dif‐
fers from other bileaflet mechanical valves in that it is made from pure pyrolytic carbon.
The PROACT (Prospective Randomized On-X R Valve Anticoagulation Trial) study is an
FDA-approved multicenter trial, sponsored by MCRI, currently enrolling patients to deter‐
mine whether or not defined patient groups receiving AVR (low versus high risk for TE
events) with the On-X R _ valve may be safely maintained on lower doses of warfarin or,
for patients in the lowrisk aortic valve arm, on antiplatelet drugs (aspirin plus clopidog‐
rel) alone compared with standard anticoagulation regimens. No single mechanical valve
has shown superior patient outcomes, and all  demonstrate extremely low rates of struc‐
tural valve deterioration, the major advantage of mechanical valves.3
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 (a) (b) (c) 
Figure 2. Mechanical valves: a) Starr-Edwards cage-ball valve, b) Bjork-Shiley mono-leaflet valve and c) St. Jude Medi‐
cal bileaflet valve
3. Biological prosthesis
The biological prostheses include a wide variety of devices. Included within this broad
category are the bioprostheses, a term which is used for valves with non-viable tissue of
biological origin. The bioprostheses include the heterografts, composed of porcine (actual
valves of a pig) or bovine tissue (pericardium of a cow) and the allografts, which are preserved
human aortic valves. The initial bioprostheses were mounted on stents to which the leaflets
and sewing ring were attached but subsequently stentless valves, which are sewn in free hand,
have been developed.[13] Stented bioprosthetic valves, which incorporate a semi-rigid
external support structure for the valve leaflets, represent the majority of tissue valves
implanted in clinical practice. The external support provides accurate valve mounting,
improving ease of implantation. Two types of stented bioprosthetic valves are currently
available in the United States: porcine aortic valves, which incorporate chemically stabilized
porcine valve leaflets mounted on a stented structure or frame, and bovine pericardial valves.
The leaflets of the latter valve type are constructed from bovine pericardium and subsequently
mounted on a stented frame. Available porcine valves include the Medtronic Mosaic valve
(Medtronic Inc., Minneapolis, MN), the St. Jude Medical Biocor and Biocor Supra valves (St.
Jude Medical, Inc., St. Paul, MN), and the Carbomedics Mitroflow valve (Carbomedics, Inc.,
Austin, TX). Bovine pericardial valves include the Carpentier–Edwards (C–E) Perimount
(Edward Lifesciences, Irvine, CA) and the CE Perimount Magna valves as well as the Sorin
Soprano (Sorin Group, Saluggia, Italy) valves. At present, based on the best available data, no
one bioprosthetic valve appears superior with regard to patient outcomes and none requires
systemic anticoagulation with warfarin, which is their major advantage. Their major disad‐
vantage is the incidence of structural valve deterioration and subsequent need for reoperation,
although the lifespan of the latest generation of tissue valves is unknown. Recent evidence also
suggests that stentless biological valves may have better coronary flow reserve compared to
stented valves. Additionally, compared with stented bovine pericardial valves, stentless valves
have been associated with increased transvalvular EOA and decreased pressure gradients
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during extended follow-up. However, as seen in other studies, LV mass regression after
stentless valve implantation was not different from stented aortic bioprostheses.[3,14]
 
(a) (b) (c) 
Figure 3. Biological prosthesis: a) stented porcine bioprosthesis, b) pericardial bovine bioprosthesis and c) stentless
porcine bioprosthesis
4. Outcomes after aortic valve replacement
The Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve
Morbidity of the American Association of Thoracic Surgery and the Society of Thoracic
Surgeons published guidelines during years, which are now widely used in reporting
outcomes after valve surgery. They presented a list of developing specific valve-related events
during patients remaining lifetime. These valve-related events are:
1. Structural valvular deterioration
2. Nonstructural dysfunction
3. Valve thrombosis
4. Embolism
5. Valvular endocarditis and
6. Bleeding events.[7, 15]
Structural valvular deterioration - Any change in function or deterioration (a decrease of
one New York Heart Association functional class or more) of an operated valve due to an
intrinsic  abnormality,  which  causes  stenosis  or  regurgitation.  Changes  intrinsic  to  the
valve include wear,  fracture,  poppet escape, calcification, leaflet  tear stent creep and su‐
ture  line  disruption  of  the  components  of  the  operated  valve.  The  definition  excludes
changes due to infection or thrombosis. Mechanical prostheses are extremely resistant to ma‐
terial fatigue or structural valve deterioration. This is characteristic of mechanical valves
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whether they are aortic  or  mitral  valves.[16]  Because of  the long-term durability of  me‐
chanical prostheses a valve replacement rate is less than 2% over 25 years. The most com‐
mon reasons for reimplantation are pre- and postoperative endocarditis, paravalvular leak
and valve thrombosis.[17]  Bioprosthetic  valves  are  not  as  durable,  have a shorter  lifespan
and are more susceptible to calcification than human and mechanical valves.[13] Biopros‐
theses have a significantly higher rate of reoperation due to structural valve deterioration.
In large series,  freedom from reoperation is  >  90% at  10  years,  but  <  70 % at  15  years.
[17,18,19]  There  is  an  important  predisposition  for  premature  bioprosthetic  structural
valve deterioration in younger patients, especially those under the age of 40 years.[17]
Nonstructural dysfunction - Any abnormality that is not intrinsic to the valve per se, which
causes stenosis or regurgitation. Examples for this include entrapment of pannus, tissue or
suture; paravalvular leak; inappropriate sizing or positioning; residual leak and clinically
important hemolytic anemia. This definition also excludes changes due to infection and
thrombosis. Subvalvular pannus formation is rare with mechanical bileaflet valves.[20] Panus
overgrowth and prosthetic structural degeneration interfering with normal valve opening and
closure may cause hemolysis severe enough for reoperation. Paravalvular leak is an operative
complication and it is related to operative technique and to endocarditis.[21]
Valve thrombosis – Any thrombus, in the absence of infection, which is attached to or near an
operated valve that occludes part of the blood flow path or that interferes with function of the
valve. The incidence of prosthesis thrombosis is < 0.2 % per year and it occurs more often in
mechanical prostheses.[22] It is most commonly due to inadequate anticoagulation or noncom‐
pliance. Freedom from valve thrombosis at 20 years is > 97 %.[23,24]
Embolism – Any embolic event that occurs, in the absence of infection, after the immediate
peri-operative period. This could be either a neurologic or peripheral embolic event. A
neurologic event includes any new, temporary or permanent focal or global neurologic deficit.
A peripheral embolic event is due to an embolus that produces symptoms from obstruction of
a peripheral (non-cerebral) artery. The incidence of thromboembolic events between biopros‐
theses and mechanical prostheses are the same.[25] This is a continuous risk factor that is
present through the life of patients with mechanical valve prosthesis, so they must maintain
therapeutic anticoagulant levels. The embolic risk is highest in the first few months, before the
ring and valve components have fully endothelialized.[26] Acceptable thromboembolic rates
range between 0.8 and 2.3 % per patient-year.[21,22,25] 50 % of these events are neurologic, 40
% are transient and 10 % are peripheral.[21]
Valvular endocarditis – Any infection involving an operated valve diagnosed by customary
clinical criteria. It is rare case with prophylactic antibiotics. Around 60 % of events occur early
and are associated with staphylococci. The mortality for this event is high. Freedom from
endocarditis with mechanical prosthesis is 97 to 98 % at 20 to 25 years. A number of studies
have reported a higher incidence of valvular endocarditis after mechanical valve replacement
in comparison with the biologic valve replacement during the initial few months after
implantation. Bioprostheses are less susceptible to early infection, which is often restricted to
the leaflets, making cure with antibiotics more likely but increasing the chances of late failure
due to degeneration of the cusps.[27,28,29]
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Bleeding event – Formerly classified as anti-coagulant hemorrhage, a bleeding event is an
episode of major internal or external bleeding that causes death, hospitalization, and perma‐
nent injury or requires transfusion. This definition applies to all patients, irrespective of anti-
coagulation status. Mechanical valves are durability but anticoagulation is key of long-term
success. International Normalized Ratio (INR) is the standard to which anticoagulation levels
should be targeted. Level of INR should be individual for each person. Complications occur
during fluctuations in the INR and less during steady-state levels, be they high or low.[30,31]
When levels of INR increase, bleeding episodes become more common, and when levels of
INR decrease thromboembolic episodes become more common. Some studies showed that
around 40 % of the bleeding episodes occurred in the first year after surgery, when levels of
INR are more likely to fluctuate. Many studies suggested that in the early postoperative period
slowly raise the level of INR to therapeutic levels is needed, to prevent bleeding events.
[21,32,33] According to ACC and ACH after mechanical AVR, the goal of antithrombotic
therapy is usually to achieve an INR of 2.5 to 3.5 for the first 3 months after surgery and 2.0 to
3.0 beyond that time. At that level of anticoagulation, the risk of significant hemorrhage
appears to be 1% to 2% per year.7 Low-dose aspirin is also indicated in addition to warfarin to
result in a lower incidence of thromboembolic event, with a low possibility for bleeding.[34]
Older patients are at higher risk for thromboembolic event because of the greater number of
risk factors that accumulate with aging.[30] Anticoagulation-related hemorrhage (ARH) is the
most common valve-related event. More often it will occur during fluctuations in INR, which
happens most often early after valve replacement.[21,22] The most common places for ARH
are gastrointestinal tract and central nervous system.[21] Acceptable ARH rates range from
1.0 to 2.5% per patient-year in long term reports.[21,22,25,35] It is very dangerous complication,
because mortality more often occurs in relation to bleeding events than in relation to throm‐
boembolic events.[21]
Operative mortality – Operative mortality is defined as all-cause mortality within 30 days of
operation. According to the Society of Thoracic Surgeons mortality for isolated AVR is 4.3%
and for AVR with concomitant coronary artery disease is 8%.[36] Many factors have been
associated with an increased risk of operative mortality in isolated AVR. Some of these risk
factors are age, female gender, diabetes, renal failure, and emergency status, previous
operation, advanced preoperative NYHA class, lower cardiac index, concomitant coronary
artery bypass grafting and longer aortic crossclamp and cardiopulmonary bypass time
respectively.[37] In the absence of major comorbidities and preserved ejection fraction, isolated
AVR can be performed with an expected mortality of less than 2%.[38]
Several studies have evaluated independent risk factors for operative mortality after AVR.
Five variables predictive of increased mortality risk after AVR are common to each of these
analyses: preoperative renal failure, urgency of AVR, preoperative heart failure, presence of
CAD or recent MI, and redo cardiac operation. Other factors independently associated with
operative mortality from the individual studies include preoperative atrial fibrillation, active
endocarditis, preoperative stroke, advanced age, lower body surface area, multiple valve
procedures, and hypertension. [39, 40]
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5. Factors affecting long-term outcome after AVR
• Demographic
◦ Older age
◦ Male sex
• Clinical
◦ Higher pre-operative NYHA functional class
◦ Pre-operative atrial fibrillation and non-sinus rhythm
◦ Pure aortic regurgitation
◦ Hypertension
◦ Diabetes mellitus
◦ Renal failure
• Surgery-related
◦ Longer cardiopulmonary bypass time
• Morphological
◦ Previous myocardial infarction
◦ Left ventricular structure and functional abnormality
◦ Previous aortic valve surgery
◦ Coronary artery disease (CAD)
Older patients have a lot of comorbiditis and they are at higher risk for valve-related events.
Atrial fibrillation is one of the risk factor for thromboembolism, because of that INR levels
must be higher (INR 2.5 to 3.5) than regular.[30,34] The majority of patients undergoing AVR
have other cardiac lesions, most commonly CAD, and more complex pathology has been
associated with increased risk. Combined myocardial revascularization and AVR increases
cross-clamp time and has the potential to increase perioperative myocardial infarction and
early postoperative mortality compared with patients undergoing isolated AVR.7 In addition
to severity of CAD and AS, the multivariate factors for late postoperative mortality include
low ejection fraction, severity of LV dysfunction, age greater than 70 years (especially in
women), and presence of NYHA functional class IV symptoms.[36]
6. Patient selection
Propter selection of patients for valve replacement can bring us excellent long-term results,
long-term survival and low incidence of valve-related complications.
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In some studies of patients followed over longer time frames, freedom from all valve-related
events and freedom from reoperation were improved in patients with mechanical valve
prostheses as compared to patients with biological prostheses. [9,16,25] Key of long-term
success of mechanical valve prostheses is anticoagulation. Patients that are inconsistent,
noncompliant or incapable of managing medications are not good candidates for long-term
chronic anticoagulation.[39,41] Also patients with higher levels of education and those from
geographic areas with a good medical infrastructure have better compliance with necessary
medications and anticoagulant monitoring.[31]
Many centers used bioprosthetic valves for patients who are older than 70 year, based on data
by Akins.[42] In patients younger than 60 years of age, the best solution would be implantation
of mechanical valves, based on prosthesis durability and they have low-risk for valve-related
events.[21] In decade between 60 and 70 years of age, other factors have to be taken into
account.7 According to some studies, patients over 65 years at the time of surgery should
receive a biologic valve. Patients under the age of 60 should have a mechanical prosthesis to
minimize the risk of structural failure requiring repeat AVR in an octogenarian. Patients
between 60 and 65 represent the group in whom there is still considerable debate regarding
prosthesis selection. Those patients who have comorbidities such as severe CAD may be less
likely to outlive their prosthesis and should receive a biologic valve. A detailed discussion of
these risks and benefits of prosthesis selection should occur with all patients and their families
prior to entering the operating room. [3,7,22,24,25,37,38]
In the early follow-up period, anticoagulation – related hemorrhage is the most common
unwanted event for mechanical valve prostheses. Over the first 10 years of follow-up there is
a higher incidence of valve-related events in patients with mechanical prostheses as opposed
to those with biologic valves.[32] However, in the next 10 to 20 years after AVR, the incidence
of valve failure and valve-related complications are much higher at biologic prostheses than
those with mechanical valve prostheses. Some series showed that the time to biologic valve
failure was only 7.6 years.[43] This failure rate will increase over time. However, freedom from
valve-related events is more strongly influenced by pre-existing comorbidities than the
presence of mechanical prostheses.[21], [22, 25, 31]
The elderly patient with severe aortic stenosis poses a therapeutic challenge. In considering
elderly patients for aortic valve replacement, important factors include the presence of
symptoms, physiologic age, patient expectations, anticipated future activities, and comorbid‐
ity. The operation itself carries a higher risk than in younger patients. Extensive calcification
of the aorta and annulus as well as fragile tissue presents significant technical difficulties for
the surgeon. In addition, particularly in women, the aortic root and annulus may be small and
require concomitant enlargement to accommodate the valve prosthesis. Furthermore, pro‐
truding arch atheroma occurs in one-fifth of patients > 65 years of age and significantly
increases the risk of stroke and mortality during cardiac surgery. Major postoperative
complications, nevertheless, remain high, with the incidence of permanent stroke between 4
and 6%. Rehabilitation can also be a problem, as elderly patients take longer to recover from
surgery. Survival has clearly improved in these elderly patients with severe symptomatic
aortic stenosis who undergo aortic valve replacement. Survival is 80–85% at 1 year and 60–
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70% at 5 years, which is similar to an age- and sex-matched population without aortic valve
disease. Most patients report improved functional capacity and quality of life, with more than
90% of patients feeling better after surgery.3
A major deterrent to mechanical valve replacement in the younger patient is the impact of
long-term anticoagulation. Mechanical valves are, however, more ideal for younger patients
due to their excellent durability characteristics. Most importantly, younger patients (i.e.,
patients under the age of 50 years) are a low-risk subset for valve related events. These
individuals have very few risk factors for TE, and thus anticoagulation can be run at the lower
end of the therapeutic target range, decreasing the incidence of anticoagulant-related hemor‐
rhage without altering the incidence of TE. In fact, many infants and children have been
managed with only aspirin with quite good long term results. While this is not recommended
in patients older than infancy, it is a feasible alternative. A recent study in patients under 50
years of age followed 254 patients for up to 20 years and found an exceedingly low rate of
valve related events, an exceptional long-term overall survival of nearly 88%, and event-free
survival probability of 92% at 19 years.[3,44,45]
Patients with an absolute requirement for long-term anticoagulation such as atrial fibrillation,
previous thromboembolic events, hypercoagulable state, severe LVD, another mechanical
heart valve in place, or intracardiac thrombus, should receive a mechanical valve regardless
of age. Patients in whom anticoagulation with warfarin is contraindicated, such as women of
child-bearing age wishing to become pregnant, patients with other bleeding disorders, or those
who refuse anticoagulation should receive a bioprosthesis. There is growing interest in using
mechanical prostheses in women of child-bearing age and providing anticoagulation with
subcutaneous low-molecular weight heparin injections. Patients with end-stage renal failure
were previously believed to have significantly elevated risk for early bioprosthetic structural
valve deterioration. However, increased anticoagulation- related complications are also more
likely in this group, and the current ACC/AHA guidelines do not recommend routine use of
mechanical prostheses in these patients.[3,7,8,9,10]
The decision between bioprosthetic and mechanical valve should be made by the patient with
educated input regarding the pros and cons of each option from the patient’s physicians. Today
surgeons implant bioprosthetic valves in younger patients who wish to avoid anticoagulation
due to lifestyle concerns (e.g. young, active individual, desire to become pregnant, etc.),
although surgeons generally will guide patients toward a mechanical option at the time of
redo-AVR if their life expectancy exceeds 10–15 years at that time.[3]
7. Operative technique
Aortic valve replacement is most frequently done through a median sternotomy, meaning
the  incision  is  made  by  cutting  through  the  sternum.  Once  the  pericardium  has  been
opened, the patient is put on a cardiopulmonary bypass machine. This machine takes over
the task of breathing for the patient and pumping their blood around while the surgeon
replaces the heart valve.
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Once the patient is on bypass, a cut is made in the aorta and a crossclamp applied. The surgeon
then removes the patient`s diseased aortic valve and a mechanical or biological valve is put in
its place. Once the valve is in place and aorta has been closed, the patient is taken off the heart-
lung machine. Transesophageal echocardiogram can be used to verify that the new valve is
functioning property. Pacing wires are usually put in place, so that the heart can be manually
paced should any complications arise after surgery. Drainage tubes are also inserted to drain
fluids from the chest and pericardium following surgery. These are usually removed within
36-48 hours while the pacing wires are generally left in place until right before the patient is
discharged from the hospital.
8. Patient-prosthesis mismatch
Prosthesis‐patient mismatch (PPM) is that a smaller than expected effective orifice area (IEOA)
in relation to the patient's body surface area (BSA) will result in higher transvalvar gradients.
It is condition that occurs when the valve area of a prosthetic valve is less than the area of that
patient’s normal valve.[46] Several authors suggest that prosthesis-patient mismatch occurs at
an IEOA of 0.85 cm2/m2.[46,47] Transvalvular gradients begin to rise substantially at IEOAs
below this value, and these elevated gradients potentially cause increased left ventricular work
that prevents adequate regression of left ventricular hypertrophy. Several factors including
age, body mass index (BMI), and pre-operative status of left ventricular function may poten‐
tially influence the effect of PPM on post-operative outcomes.[46] PPM is associated with a
significant reduction in cardiac index during the postoperative course. The incidence of
congestive heart failure was significantly higher in patients with PPM.[48] Several studies
reported that early mortality is significantly increased in patients with PPM.[47, 48, 49, 50]
The projected indexed EOA should be systematically calculated at the time of the operation to
estimate the risk of PPM. PPM can be avoided by using a simple strategy at the time of
operation. Pibarot suggested that surgeon first calculate the patient's BSA from his or her
weight and height. Than multiply BSA by 0.85 cm2/m2, the result being the minimum EOA that
the prosthesis to be implanted should have to avoid PPM, and than choose the prosthesis and
the reference values for the different types and sizes of prosthesis.[46, 47]
Due to concerns over PPM, stentless bioprosthetic valves,  which generally have a larger
EOA sizefor-  size compared with mechanical  or  stented bioprosthetic  valves,  have been
increasingly  utilized for  AVR.  In  initial  evaluation,  stentless  valves  had better  hemody‐
namics  and  improved  survival  rates  relative  to  stented  biological  or  mechanical  valves
and were more durable than stented biological valves. Stentless valves may be preferred
in patients with a small aortic root, and arguments have been made that wider utilization
of stentless valves may minimize PPM. Stentless valves also appear to have better hemo‐
dynamic profiles than stented valves during exercise testing. Technical reasons for not im‐
planting stentless valves include extensive aortic root calcification, coronary ostia opposed
by 180,  presence of  the two coronary ostia in close proximity,  or unusual disproportion
between the  sinotubular  junction  and the  aortic  annulus.  Whereas  stented  valves  allow
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perfect valve mounting within the aortic annulus, thus reducing the risk of implanting anincompetent  valve,  postoperative  AR and limited  durability  remain  a  concern  with  thefree-hand stentless  valve  insertion technique.  This  issue  may be  circumvented with  fullaortic root replacement using a stentless porcine root.[3.49,50]
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